Chestnut Hill, MA, United States of America

Edward Yin Shiang Lin

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 5.6

ph-index = 1

Forward Citations = 23(Granted Patents)


Location History:

  • Chestnut Hill, MA (US) (2012)
  • Cambridge, MA (US) (2022)
  • Ashland, MA (US) (2022)

Company Filing History:


Years Active: 2012-2025

where 'Filed Patents' based on already Granted Patents

7 patents (USPTO):

Title: The Innovative Contributions of Edward Yin Shiang Lin

Introduction

Edward Yin Shiang Lin is a notable inventor based in Chestnut Hill, MA (US). He has made significant contributions to the field of pharmaceuticals, holding a total of seven patents. His work focuses on developing inhibitors that have potential applications in medical treatments.

Latest Patents

Among his latest patents are the Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors. These patents describe compounds represented by a specific formula or a pharmaceutically acceptable salt thereof, along with pharmaceutical compositions and methods of preparation and use. Another significant patent involves Morpholinyl, piperazinyl, oxazepanyl, and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors, which also details compounds and their applications in the pharmaceutical field.

Career Highlights

Edward has worked with prominent companies in the biotechnology sector, including Biogen MA Inc. and Biogen Idec MA Inc. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Throughout his career, Edward has collaborated with talented individuals such as Kevin Guckian and Nathan Genung. These partnerships have fostered innovation and have been instrumental in advancing his research.

Conclusion

Edward Yin Shiang Lin's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to impact the industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…